# MPLT catalysts: MapLight Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mplt/catalysts

> MapLight Therapeutics, Inc. (MPLT) has 10 upcoming catalysts. The next is the betovumeline topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MPLT?

MapLight Therapeutics, Inc. (MPLT) has 10 upcoming catalysts. The next is the betovumeline topline data readout, 2H 2027. Press release filed with the SEC (EX-99): "VISTA, MapLight's ongoing trial designed to support registration for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, is also evaluating ML-007C-MA 210/3 mg BID (the same dose associated with the cognitive effect in ZEPHYR), with topline results expected in the second half of 2027." [Calendar and source filings](https://sec-api.dev/companies/mplt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-316820, https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086dex992.htm (retrieved 2026-11-12). Last confirmed 2026-09-09. Cite: https://sec-api.dev/companies/mplt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | MapLight Therapeutics, Inc. |
| Ticker | MPLT (Nasdaq) |
| SEC CIK | 1770069 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mplt |

## Cash runway

Cash $351.3M as of 2026-06-30; quarterly burn $44.9M; about 23.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-349554).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 4, 2025 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports Third Quarter Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm)) |
| March 10, 2026 | [Ml-004 (ir)/(er) tablet primary completion](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | completed | "NCT05081245 (ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05081245)) |
| March 26, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/mplt-ex99_1.htm)) |
| May 14, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/mplt-ex99_1.htm)) |
| June 4, 2026 | [Ml-007c-ma bid primary completion](https://sec-api.dev/pdufa/ml-007c-ma-bid) | MPLT | Schizophrenia | completed | "NCT07038876 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07038876)) |
| Jul 2026 | [MapLight Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed, positive | "In July 2026, we announced positive topline results from" ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526386648/d546679ds1.htm)) |
| Jul 2026 | [MapLight Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mplt/catalysts) | MPLT | schizophrenia experiencing an acute exacerbation of psychosis | completed, positive | "Reported positive topline results in July 2026 from the Phase 2 ZEPHYR trial of ML-007C-MA in adults with schizophrenia experiencing an acute exacerbation of psychosis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818dex991.htm)) |
| July 27, 2026 | [Betovumeline topline data readout](https://sec-api.dev/pdufa/betovumeline) | MPLT | acute exacerbation of schizophrenia | completed, positive | "(Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), in adults with an acute exacerbation of schizophrenia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086dex992.htm)) |
| Aug 2026 | [ZOMIG (zolmitriptan) topline data readout](https://sec-api.dev/pdufa/zolmitriptan) | MPLT |  | scheduled | "The Company remains well capitalized ahead of the topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in schizophrenia, expected by mid-August 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456dex992.htm)) |
| August 13, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "NEWSWIRE) — MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818dex991.htm)) |
| 2H 2027 | [Betovumeline topline data readout](https://sec-api.dev/pdufa/betovumeline) | MPLT | hallucinations and delusions associated with Alzheimer's disease psychosis | scheduled | "VISTA, MapLight's ongoing trial designed to support registration for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, is also evaluating ML-007C-MA 210/3 mg BID (the same dose associated with the cognitive effect in ZEPHYR), with topline results expected in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086dex992.htm)) |
| November 2027 | [Ml-004 (ir)/(er) tablet primary completion](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | scheduled | "NCT05889273 (ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889273)) |
| Nov 2027 to Feb 2028 | [Ml-004 (ir)/(er) tablet topline data readout](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | scheduled | "NCT05889273 (ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889273)) |
| December 2027 | [ML-007C-MA primary completion](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06887192 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06887192)) |
| Dec 2027 to Mar 2028 | [ML-007C-MA topline data readout](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06887192 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06887192)) |
| 2028 | [MapLight Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | scheduled | "End-of-Phase 2 meeting to discuss the registrational path forward, including the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818dex991.htm)) |
| March 2029 | [ML-007C-MA primary completion](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT07459660 (An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459660)) |
| Mar to Jun 2029 | [ML-007C-MA topline data readout](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT07459660 (An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459660)) |
| February 2030 | [ML-007C-MA primary completion](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Schizophrenia | scheduled | "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459647)) |
| Feb to May 2030 | [ML-007C-MA topline data readout](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Schizophrenia | scheduled | "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459647)) |

## Drugs

- [Betovumeline](https://sec-api.dev/pdufa/betovumeline): acute exacerbation of schizophrenia, hallucinations and delusions associated with alzheimer's disease psychosis
- [Ml-004 (ir)/(er) tablet](https://sec-api.dev/pdufa/ml-004-ir-er): Autism Spectrum Disorder
- [ML-007C-MA](https://sec-api.dev/pdufa/ml-007c-ma): Psychosis Associated With Alzheimer's Disease, Schizophrenia
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid): Schizophrenia
- [ZOMIG (zolmitriptan)](https://sec-api.dev/pdufa/zolmitriptan): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mplt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MPLT catalysts: MapLight Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mplt/catalysts

```bibtex
@misc{secapidev_companies_mplt_catalysts_20261116,
  title        = {MPLT catalysts: MapLight Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mplt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mplt_catalysts_20261116","title":"MPLT catalysts: MapLight Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mplt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
